PBS Biotech Joins Organoid COMMONS to Accelerate Industrialization and Scalability of Human-Relevant Models
This press release announces PBS Biotech's membership in Organoid COMMONS, an industry consortium advancing the standardization, industrialization, and commercial scalability of organoid technologies. The consortium aims to bridge academic innovation and industrial adoption while supporting reproducible human-relevant models. PBS Biotech contributes bioprocess expertise, Vertical-Wheel® Bioreactor Technology, and scalable manufacturing solutions focused on organoid yield, viability, consistency, and process scalability. Participation supports development of manufacturing standards, knowledge sharing, and broader organoid adoption across drug discovery, regenerative medicine, and biopharmaceutical development.
This document isn’t available to view yet. Browse the library
This publication reports a fully suspended process for expansion and six-stage differentiation of human induced pluripotent stem cells into stem cell-derived islets in 0.1 L and 0.5 L Vertical-Wheel® Bioreactors. A fivefold increase in vessel volume produced a twelvefold increase in islet-equivalent yield without compromising islet structure. The 27-day process generated endocrine populations expressing ?-, ?-, and ?-cell markers with glucose-responsive insulin secretion and transcriptomic characteristics approaching adult islets. The study also evaluated donor-derived iPSC lines, cellular…
This publication describes scalable generation of multilineage liver organoids from human pluripotent stem cells in a PBS-Mini Vertical-Wheel® Bioreactor. Studies evaluated how Activin A concentration directs endoderm and mesenchymal lineage development. High concentrations promoted homogeneous definitive endoderm induction and hepatic maturation markers, while lower concentrations generated early liver diverticula-like structures with lumens, hepatic mesenchyme, endothelial markers, and extracellular matrix organization. Transcriptomic, immunohistochemical, and developmental analyses …
This publication describes scalable human pluripotent stem cell expansion and growth factor-directed cardiomyocyte differentiation in Vertical-Wheel® Bioreactors. Studies evaluated inoculation, agitation, medium exchange, aggregate size, metabolism, viability, and pluripotency before optimizing differentiation with BMP4, Activin A, and bFGF. The process produced more than one million cardiac troponin T-positive cells/mL and was reproduced at 500 mL, averaging 1.11 million cardiomyocytes/mL and 93% cardiac purity. Cells displayed expected electrophysiological and contractile properties and…
How Can We Help?
Tell us what you need and we’ll take it from there.